Gordon Ramage is a Professor of Infection Prevention and Control at Glasgow Caledonian University and has been a principal investigator and group leader since 2004. He has a long standing interest in fungal biofilms of clinical importance, having trained under Prof Jose Lopez Ribot at the University of Texas Health Science Centre at San Antonio, Texas. Gordon has since built a career on focusing on developing fungal biofilm models to evaluate new and existing antifungals and in evaluating the clinical impact of fungal and interkingdom biofilms. Gordon is a previous Secretary of the British Society for Medical Mycology and an Honorary member, a Fellow of the European Confederation of Medical Mycology, and was the Chair of the ESCMID Study Group for Biofilms (2021-2025). He is also the founding member of the Glasgow Biofilm Research Network.Dr. David Andes, a distinguished faculty member and chief of the Division of Infectious Disease, holds the William A. Craig Endowed Professorship and directs the Wisconsin Antimicrobial Drug Discovery and Development NIH Center of Excellence. He earned a National Institutes of Health Mentored Clinical Scientist Development Award and an American Society for Microbiology ICAAC Young Investigator Award. As a Fellow of the Infectious Diseases Society of America and the American Academy of Microbiology, he served as the past president of the International Society of Antimicrobial Pharmacology. Dr. Andes contributes significantly to organizations like the American Society of Clinical Investigation and the Clinical Laboratory Standards Institute Antifungal Committee. With editorial roles in seven prestigious journals, including Antimicrobial Agents and Chemotherapy, and as a permanent study member for the NIH, he continues to make profound contributions to the field.

• Chapter 1: Oral Candidiasis.- Chapter 2: Cross Kingdom communication The interplay between Candida albicans and Streptococcus mutans.- Chapter 3: The Formation and Prevention of Biofilms on Airway Management Devices.- Chapter 4: Exploring the Oral Mycobiome Biofilms and Inter Kingdom Interactions in Health and Disease.- Chapter 5: Vulvovaginal Candidiasis Pathophysiology, the role of biofilms, and emerging therapeutics.- Chapter 6: Prevalence and influence of fungal biofilm in wound infections.- Chapter 7: Candida auris implications for infection prevention and control in the management of this resilient biofilm former.- Chapter 8: Composition and Role of the Extracellular Matrix in Fungal Biofilm Drug Resistance.- Chapter 9: Fungal Biofilm Dispersal.- Chapter 10: Candida biofilms and Immunity.- Chapter 11: Novel therapeutic approaches to control fungal biofilms.- Chapter 12: Large Scale Phenotypic Screenings of Repurposing Libraries to Identify Drugs with Novel Antifungal Activity against Candida Biofilms.- Chapter 13: Aspergillus Biofilms.- Chapter 14: Assays to interrogate Aspergillus fumigatus biofilm fitness.- Chapter 15: Implications of fungal biofilms in microbial keratitis.

Gordon Ramage is a Professor of Infection Prevention and Control at Glasgow Caledonian University and has been a principal investigator and group leader since 2004. He has a long standing interest in fungal biofilms of clinical importance, having trained under Prof Jose Lopez Ribot at the University of Texas Health Science Centre at San Antonio, Texas. Gordon has since built a career on focusing on developing fungal biofilm models to evaluate new and existing antifungals and in evaluating the clinical impact of fungal and interkingdom biofilms. Gordon is a previous Secretary of the British Society for Medical Mycology and an Honorary member, a Fellow of the European Confederation of Medical Mycology, and was the Chair of the ESCMID Study Group for Biofilms (2021-2025). He is also the founding member of the Glasgow Biofilm Research Network.Dr. David Andes, a distinguished faculty member and chief of the Division of Infectious Disease, holds the William A. Craig Endowed Professorship and directs the Wisconsin Antimicrobial Drug Discovery and Development NIH Center of Excellence. He earned a National Institutes of Health Mentored Clinical Scientist Development Award and an American Society for Microbiology ICAAC Young Investigator Award. As a Fellow of the Infectious Diseases Society of America and the American Academy of Microbiology, he served as the past president of the International Society of Antimicrobial Pharmacology. Dr. Andes contributes significantly to organizations like the American Society of Clinical Investigation and the Clinical Laboratory Standards Institute Antifungal Committee. With editorial roles in seven prestigious journals, including Antimicrobial Agents and Chemotherapy, and as a permanent study member for the NIH, he continues to make profound contributions to the field.

• Chapter 1: Oral Candidiasis.- Chapter 2: Cross Kingdom communication The interplay between Candida albicans and Streptococcus mutans.- Chapter 3: The Formation and Prevention of Biofilms on Airway Management Devices.- Chapter 4: Exploring the Oral Mycobiome Biofilms and Inter Kingdom Interactions in Health and Disease.- Chapter 5: Vulvovaginal Candidiasis Pathophysiology, the role of biofilms, and emerging therapeutics.- Chapter 6: Prevalence and influence of fungal biofilm in wound infections.- Chapter 7: Candida auris implications for infection prevention and control in the management of this resilient biofilm former.- Chapter 8: Composition and Role of the Extracellular Matrix in Fungal Biofilm Drug Resistance.- Chapter 9: Fungal Biofilm Dispersal.- Chapter 10: Candida biofilms and Immunity.- Chapter 11: Novel therapeutic approaches to control fungal biofilms.- Chapter 12: Large Scale Phenotypic Screenings of Repurposing Libraries to Identify Drugs with Novel Antifungal Activity against Candida Biofilms.- Chapter 13: Aspergillus Biofilms.- Chapter 14: Assays to interrogate Aspergillus fumigatus biofilm fitness.- Chapter 15: Implications of fungal biofilms in microbial keratitis.

Gordon Ramage is a Professor of Infection Prevention and Control at Glasgow Caledonian University and has been a principal investigator and group leader since 2004. He has a long standing interest in fungal biofilms of clinical importance, having trained under Prof Jose Lopez Ribot at the University of Texas Health Science Centre at San Antonio, Texas. Gordon has since built a career on focusing on developing fungal biofilm models to evaluate new and existing antifungals and in evaluating the clinical impact of fungal and interkingdom biofilms. Gordon is a previous Secretary of the British Society for Medical Mycology and an Honorary member, a Fellow of the European Confederation of Medical Mycology, and was the Chair of the ESCMID Study Group for Biofilms (2021-2025). He is also the founding member of the Glasgow Biofilm Research Network.Dr. David Andes, a distinguished faculty member and chief of the Division of Infectious Disease, holds the William A. Craig Endowed Professorship and directs the Wisconsin Antimicrobial Drug Discovery and Development NIH Center of Excellence. He earned a National Institutes of Health Mentored Clinical Scientist Development Award and an American Society for Microbiology ICAAC Young Investigator Award. As a Fellow of the Infectious Diseases Society of America and the American Academy of Microbiology, he served as the past president of the International Society of Antimicrobial Pharmacology. Dr. Andes contributes significantly to organizations like the American Society of Clinical Investigation and the Clinical Laboratory Standards Institute Antifungal Committee. With editorial roles in seven prestigious journals, including Antimicrobial Agents and Chemotherapy, and as a permanent study member for the NIH, he continues to make profound contributions to the field.

• Chapter 1: Oral Candidiasis.- Chapter 2: Cross Kingdom communication The interplay between Candida albicans and Streptococcus mutans.- Chapter 3: The Formation and Prevention of Biofilms on Airway Management Devices.- Chapter 4: Exploring the Oral Mycobiome Biofilms and Inter Kingdom Interactions in Health and Disease.- Chapter 5: Vulvovaginal Candidiasis Pathophysiology, the role of biofilms, and emerging therapeutics.- Chapter 6: Prevalence and influence of fungal biofilm in wound infections.- Chapter 7: Candida auris implications for infection prevention and control in the management of this resilient biofilm former.- Chapter 8: Composition and Role of the Extracellular Matrix in Fungal Biofilm Drug Resistance.- Chapter 9: Fungal Biofilm Dispersal.- Chapter 10: Candida biofilms and Immunity.- Chapter 11: Novel therapeutic approaches to control fungal biofilms.- Chapter 12: Large Scale Phenotypic Screenings of Repurposing Libraries to Identify Drugs with Novel Antifungal Activity against Candida Biofilms.- Chapter 13: Aspergillus Biofilms.- Chapter 14: Assays to interrogate Aspergillus fumigatus biofilm fitness.- Chapter 15: Implications of fungal biofilms in microbial keratitis.